BioSpace News Archive

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), is pleased to provide an update on the development activities of the Company’s patented reformulated enteric coated version of orally

Vertex Pharmaceuticals Incorporated announced that three of its researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for developing life-transforming drug combinations that repair the defective chloride channel protein in patients with cystic fibrosis.” Specifically, the award celebrates the work of Paul Negulescu, Ph.D., Fredrick Van Goor, Ph.D., and Sabine Hadida, Ph.D., who have worked together to lead cystic fibrosis discovery for over 20 years.

MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio”), Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders.

Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity, proudly announces the appointment of Dr. Timothy Kieffer as its Chief Scientific Officer.

The American Urological Association released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system and The Copenhagen University, publish a study today in the journal Cell titled “Complex effects of sequence variants on lipid levels and coronary artery disease”.

Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.

New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.

TRANSGENE, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that Management will participate in several investor events, as set out below.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.